SS-31 (Elamipretide)

SS-31, also known as elamipretide, represents a novel class of mitochondria-targeting therapeutics designed to address age-related mitochondrial dysfunction. Research indicates this synthetic tetrapeptide can cross cellular membranes and selectively accumulate in mitochondria, where it binds to cardiolipin and helps stabilize the inner mitochondrial membrane structure. Studies suggest SS-31 may improve mitochondrial bioenergetics, reduce oxidative stress, and potentially slow cellular aging processes.

Clinical trials have investigated SS-31 for various conditions including primary mitochondrial myopathy, Barth syndrome, and heart failure with preserved ejection fraction. Research indicates the compound is generally well-tolerated in clinical settings, though some participants have reported injection site reactions and gastrointestinal effects. The drug requires subcutaneous injection and has shown variable efficacy across different patient populations and conditions.

Currently, SS-31 remains an investigational drug available only through clinical trials or compassionate use programs. Studies suggest it may hold promise for treating mitochondrial diseases and age-related conditions, but research is ongoing to establish optimal dosing, patient selection criteria, and long-term safety profiles. The high cost and limited availability make it accessible primarily to patients with severe mitochondrial disorders enrolled in formal research studies.